SARS-CoV-2 Neutralizing Antibodies Detection Kit
|Synonyms||COVID-19 Neutralizing Antibodies Detection Kit; 2019-nCoV Neutralizing Antibodies Detection Kit; 2019-nCoV Spike Protein S1 (RBD) Neutralizing Antibodies Detection Kit|
|Application Set||Qualitative ELISA|
To measure the presence of neutralizing/blocking antibodies in human serum/plasma that inhibit the binding of the SARS-CoV-2 Spike (RBD) protein to its human receptor ACE2.
Contains sufficient materials for 96 reactions
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||+4°C|
After standard reconstitution, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Plate and reagents should reach room temperature before use.
|Use/Stability||12 months after the day of manufacturing. See expiry date on ELISA Kit box.|
|Product Specification Sheet|
Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many other wild animals. Recently, a new severe acute respiratory syndrome β-coronavirus called SARS-CoV-2 has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells.The SARS-CoV-2 Neutralizing Antibodies Detection Kit contains key reagents required to test the presence of functional neutralizing antibodies against SARS-CoV-2 present in the serum or plasma. It is an easy and fast alternative to the classical neutralization assay using Vero E6 cells. This Detection Kit is based on a colorimetric reaction, which measures the binding of the RBD of the Spike S protein from SARS-CoV-2 to its human receptor ACE2. The presence of neutralizing / blocking antibodies in the samples are detected by reduction of signal indicating the inhibition of the Spike-ACE2 binding.
- Comparison of two commercial surrogate ELISAs to detect a neutralizing antibody response to SARS-CoV-2: K. Mueller, et al.; J. Virol. Methods 292, 114122 (2021)
- Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals: H. Lingel, et al.; J. Autoimmun. 122, 102682 (2021)
- Evaluation of Two Rapid Lateral Flow Tests and Two Surrogate ELISAs for the Detection of SARS-CoV-2 Specific Neutralizing Antibodies: P. Girl, et al.; SSRN 3963559 (2021)